Clinical Pearls for Early Career Success: Proceedings from The 2018 Retina Fellow Summit

These activities provide retina fellows and retina specialists with education that addresses the latest clinical data, translational research, and pearls for transitioning from fellowship.

Click Below for Faculty Introductions

TARGET AUDIENCE

This activity has been designed to meet the educational needs of retina fellows, ophthalmology residents, retina specialists, and comprehensive ophthalmologists who treat diseases of the retina.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Evaluate and interpret the expanding literature regarding treatment of retinal vascular diseases.
  2. Develop optimal, individualized management plans by applying the latest clinical data.
  3. Describe considerations in making transitions to practice.
  4. Discuss practical aspects of achieving success in practice.

FACULTY

Diana V. Do, MD, FAAO (Course Director)
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine

Quan Dong Nguyen, MD, MSc, FAAO (Course Director)
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine

Robert Bhisitkul, MD, PhD
Professor of Ophthalmology
University of California, San Francisco

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Jonathan L. Prenner, MD
Clinical Professor and Chairman
Department of Ophthalmology
Rutgers Robert Wood Johnson Medical School

Christina Y. Weng, MD, MBA
Assistant Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor College of Medicine

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Diana V. Do, MD, FAAO

Research Support: BioTime, Genentech, Regeneron, Santen

Scientific Advisory Board: Allergan, Clearside, Genentech, Kodiak, Regeneron

Quan Dong Nguyen, MD, MSc, FAAO

Consultant/Advisor: ???
Grant/Research Support: ???

Research Support: Gilead, Genentech, KalVista, Regeneron, Santen

Scientific Advisory Board: EyePoint, Gilead, Genentech, Regeneron, Santen

Robert Bhisitkul, MD, PhD

Consultant/Advisor: Ribomic, Inc, Quark, AntriaBio

Grant/Research Support: Genentech

Stock Ownership: Zordera Co-Founder

Peter K. Kaiser, MDConsultant/Advisor: Aerie, Aerpio, Alcon, Allegro, Allergan, Bayer, Bausch and Lomb
Jonathan L. Prenner, MDConsultant/Advisor: Alcon
Christina Y. Weng, MD, MBAConsultant/Advisor: Allergan, Alimera Sciences, Inc

Non-faculty: Alison Kemp, Bernard M. Abrams, MD, Louis Settembrino, CHCP, and Christina M. Ohnsman, MD, hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Catalyst Medical Education, LLC., and Regeneron Pharmaceuticals Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Non-physician
Course opens: 
11/15/2018
Course expires: 
11/14/2019
Rating: 
0

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Non-physician

Accreditation Period

Course opens: 
11/15/2018
Course expires: 
11/14/2019
Please login or register to take this course.